Novartis AG
ISIN US66987V1098
|WKN 907122
Overview
Description
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Healthcare Biopharmaceuticals Other Biopharmaceuticals Switzerland
Chart
Financials
Key metrics
| Market capitalisation, EUR | 213,906.29 m |
| EPS, EUR | 7.96 |
| P/B ratio | 4.76 |
| P/E ratio | 11.94 |
| Dividend yield | 3.10% |
Income statement (2023)
| Revenue, EUR | 42,031.24 m |
| Net income, EUR | 7,925.26 m |
| Profit margin | 18.86% |
What ETF is Novartis AG in?
There are 2 ETFs which contain Novartis AG. All of these ETFs are listed in the table below. The ETF with the largest weighting of Novartis AG is the L&G Pharma Breakthrough UCITS ETF.
| ETF | Weight | Investment focus | Holdings | TER | Fund size (in m EUR) | Return 1Y | WKN | ISIN |
|---|---|---|---|---|---|---|---|---|
| First Trust Value Line® Dividend Index UCITS ETF Acc | 0.48% | Equity United States Dividend | 206 | 0.70% | 8 | +23.04% | A2PZMV | IE00BKVKW020 |
| L&G Pharma Breakthrough UCITS ETF | 2.66% | Equity World Health Care Innovation | 37 | 0.49% | 15 | +4.47% | A2H9XR | IE00BF0H7608 |
Performance
Returns overview
| YTD | +3.16% |
| 1 month | -9.08% |
| 3 months | -9.18% |
| 6 months | +0.79% |
| 1 year | +7.17% |
| 3 years | +33.89% |
| 5 years | - |
| Since inception (MAX) | +16.43% |
| 2023 | +4.16% |
| 2022 | +16.57% |
| 2021 | - |
| 2020 | - |
Monthly returns in a heat map
Risk
Risk metrics in this section:
- Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
- Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
- Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
Risk overview
| Volatility 1 year | 16.19% |
| Volatility 3 years | 18.93% |
| Volatility 5 years | - |
| Return per risk 1 year | 0.44 |
| Return per risk 3 years | 0.54 |
| Return per risk 5 years | - |
| Maximum drawdown 1 year | -12.83% |
| Maximum drawdown 3 years | -14.51% |
| Maximum drawdown 5 years | - |
| Maximum drawdown since inception | -14.67% |
Rolling 1 year volatility
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.